New targeted drug tested for Tough-to-Treat lung cancers
Disease control
Terminated
This study tested a new type of targeted cancer drug called MYTX-011 in people with advanced non-small cell lung cancer (NSCLC) that had progressed after standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors, especially in patients w…
Phase: PHASE1 • Sponsor: Mythic Therapeutics • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC